From Proteopedia
(Difference between revisions)
proteopedia linkproteopedia link
|
|
| Line 1: |
Line 1: |
| - | [[Image:2op9.gif|left|200px]] | + | {{Seed}} |
| | + | [[Image:2op9.png|left|200px]] |
| | | | |
| | <!-- | | <!-- |
| Line 9: |
Line 10: |
| | {{STRUCTURE_2op9| PDB=2op9 | SCENE= }} | | {{STRUCTURE_2op9| PDB=2op9 | SCENE= }} |
| | | | |
| - | '''Substrate Specificity Profiling and Identification of a New Class of Inhibitor for the Major Protease of the SARS Coronavirus'''
| + | ===Substrate Specificity Profiling and Identification of a New Class of Inhibitor for the Major Protease of the SARS Coronavirus=== |
| | | | |
| | | | |
| - | ==Overview==
| + | <!-- |
| - | Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a high rate of mortality. The SARS-associated coronavirus (SARS-CoV) has been identified as the etiological agent of the disease. Although public health procedures have been effective in combating the spread of SARS, concern remains about the possibility of a recurrence. Various approaches are being pursued for the development of efficacious therapeutics. One promising approach is to develop small molecule inhibitors of the essential major polyprotein processing protease 3Clpro. Here we report a complete description of the tetrapeptide substrate specificity of 3Clpro using fully degenerate peptide libraries consisting of all 160,000 possible naturally occurring tetrapeptides. The substrate specificity data show the expected P1-Gln P2-Leu specificity and elucidate a novel preference for P1-His containing substrates equal to the expected preference for P1-Gln. These data were then used to develop optimal substrates for a high-throughput screen of a 2000 compound small-molecule inhibitor library consisting of known cysteine protease inhibitor scaffolds. We also report the 1.8 A X-ray crystal structure of 3Clpro bound to an irreversible inhibitor. This inhibitor, an alpha,beta-epoxyketone, inhibits 3Clpro with a k3/Ki of 0.002 microM(-1) s(-1) in a mode consistent with the substrate specificity data. Finally, we report the successful rational improvement of this scaffold with second generation inhibitors. These data provide the foundation for a rational small-molecule inhibitor design effort based upon the inhibitor scaffold identified, the crystal structure of the complex, and a more complete understanding of P1-P4 substrate specificity.
| + | The line below this paragraph, {{ABSTRACT_PUBMED_17605471}}, adds the Publication Abstract to the page |
| | + | (as it appears on PubMed at http://www.pubmed.gov), where 17605471 is the PubMed ID number. |
| | + | --> |
| | + | {{ABSTRACT_PUBMED_17605471}} |
| | | | |
| | ==About this Structure== | | ==About this Structure== |
| Line 29: |
Line 33: |
| | [[Category: Proteinase]] | | [[Category: Proteinase]] |
| | [[Category: Sar]] | | [[Category: Sar]] |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 11:22:29 2008'' | + | |
| | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 12:14:16 2008'' |
Revision as of 09:14, 28 July 2008
Template:STRUCTURE 2op9
Substrate Specificity Profiling and Identification of a New Class of Inhibitor for the Major Protease of the SARS Coronavirus
Template:ABSTRACT PUBMED 17605471
About this Structure
2OP9 is a Single protein structure of sequence from Sars coronavirus. Full crystallographic information is available from OCA.
Reference
Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus., Goetz DH, Choe Y, Hansell E, Chen YT, McDowell M, Jonsson CB, Roush WR, McKerrow J, Craik CS, Biochemistry. 2007 Jul 31;46(30):8744-52. Epub 2007 Jul 3. PMID:17605471
Page seeded by OCA on Mon Jul 28 12:14:16 2008
